[go: up one dir, main page]

BR0207549A - Compostos tricìclicos moduladores de receptor de androgênio e métodos - Google Patents

Compostos tricìclicos moduladores de receptor de androgênio e métodos

Info

Publication number
BR0207549A
BR0207549A BR0207549-0A BR0207549A BR0207549A BR 0207549 A BR0207549 A BR 0207549A BR 0207549 A BR0207549 A BR 0207549A BR 0207549 A BR0207549 A BR 0207549A
Authority
BR
Brazil
Prior art keywords
methods
androgen receptor
receptor modulating
tricyclic compounds
compounds
Prior art date
Application number
BR0207549-0A
Other languages
English (en)
Inventor
Lin Zhi
Cornelis Arjan Van Oeveren
Jyun-Hung Chen
Robert I Higuchi
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Publication of BR0207549A publication Critical patent/BR0207549A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)

Abstract

"COMPOSTOS TRICìCLICOS MODULADORES DE RECEPTOR DE ANDROGêNIO E MéTODOS". A presente invenção refere-se aos compostos tricíclicos não-esteroidais que são moduladores de receptores de androgênio e aos métodos para produzir e usar tais compostos.
BR0207549-0A 2001-02-23 2002-02-23 Compostos tricìclicos moduladores de receptor de androgênio e métodos BR0207549A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27118901P 2001-02-23 2001-02-23
PCT/IB2002/000537 WO2002066475A2 (en) 2001-02-23 2002-02-23 Tricyclic androgen receptor modulator compounds

Publications (1)

Publication Number Publication Date
BR0207549A true BR0207549A (pt) 2004-08-03

Family

ID=23034558

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207549-0A BR0207549A (pt) 2001-02-23 2002-02-23 Compostos tricìclicos moduladores de receptor de androgênio e métodos

Country Status (9)

Country Link
US (3) US7026484B2 (pt)
EP (1) EP1363909B1 (pt)
JP (3) JP4578053B2 (pt)
CN (2) CN100590124C (pt)
AU (1) AU2002236114A1 (pt)
BR (1) BR0207549A (pt)
CA (1) CA2434299C (pt)
MX (1) MXPA03007421A (pt)
WO (1) WO2002066475A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1212330B1 (en) * 1999-08-27 2006-04-19 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US7026484B2 (en) 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
US7214690B2 (en) * 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
FR2825268B1 (fr) 2001-05-31 2004-09-17 Oreal Composition cosmetique comprenant des particules de carbonate de calcium et des agents de conditionnement
JP2005509629A (ja) * 2001-10-19 2005-04-14 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体モジュレーターおよびその使用方法
AU2003214879B2 (en) * 2002-01-22 2008-02-07 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
US6858621B2 (en) 2002-04-26 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. 2-(quinolonyl)-fused heterocycles as androgen receptor modulators
JPWO2004066994A1 (ja) * 2003-01-28 2006-05-18 関西ティー・エル・オー株式会社 抗癌剤
US7227023B2 (en) 2003-04-30 2007-06-05 Wyeth Quinoline 3-amino chroman derivatives
JP4709759B2 (ja) * 2003-08-22 2011-06-22 リガンド・ファーマシューティカルズ・インコーポレイテッド アンドロゲン受容体モジュレーター化合物としての６−シクロアミノ−２−キノリノン誘導体
WO2005090282A1 (en) 2004-03-12 2005-09-29 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
CN104803916B (zh) * 2004-11-16 2017-08-11 詹森药业有限公司 用作选择性雄激素受体调节剂(sarms)的杂环衍生物
MX2007009784A (es) * 2005-06-17 2007-09-26 Ligand Pharm Inc Compuestos moduladores de receptores de androgenos y metodos.
JP2009506077A (ja) * 2005-08-26 2009-02-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 非ステロイド性抗アンドロゲン剤
DE102006029446A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Neue 3-substituierte-Chinoline als Kinase-Inhibitoren
DE102006029445A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Neue 3-Cyano-chinoline als Kinase-Inhibitoren
EP2137903B1 (en) * 2007-03-16 2011-01-19 Telefonaktiebolaget LM Ericsson (publ) Interface selection in a moving network
EP2222636B1 (en) * 2007-12-21 2013-04-10 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
EP2130831A1 (en) 2008-06-06 2009-12-09 InterMed Discovery GmbH CDC25 inhibitors
US20120245205A1 (en) 2009-07-29 2012-09-27 Delong Mitchell A Compositions and methods for inhibiting hair growth
EP2671585B1 (en) 2011-01-31 2016-07-13 Toray Industries, Inc. (-)-17-(cyclopropylmethyl)-3,14ß-dihydroxy-4,5a-epoxy-6ß-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan for use in treating or preventing cancer cachexia
TWI537274B (zh) * 2011-03-14 2016-06-11 橘生藥品工業股份有限公司 新穎之八氫噻吩并喹啉衍生物、含有其之醫藥組成物及該等之用途
CN106543197B (zh) * 2016-11-09 2018-07-20 中国科学院新疆理化技术研究所 一种补骨脂素席夫碱类衍生物及用途
CN106565734B (zh) * 2016-11-09 2018-07-03 中国科学院新疆理化技术研究所 一种补骨脂素酯类衍生物及用途
EP4032609A1 (en) 2018-09-27 2022-07-27 Chevron Phillips Chemical Company LP Processes for producing fluorided solid oxides and uses thereof in metallocene-based catalyst systems
CA3158632A1 (en) 2019-10-24 2021-04-29 Toray Industries, Inc. Therapeutic or prophylactic agent for cachexia
EP4173624A4 (en) 2020-06-30 2024-08-14 Toray Industries, Inc. AMELIORATE OR PROPHYLACTIC AGENT FOR SYMPTOM OF MUSCLE WEAKNESS IN A DISEASE OR SYNDROME ASSOCIATED WITH A METABOLIC DISORDER

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2126811A1 (en) 1971-05-29 1972-12-14 Basf Ag Fluorescent pigments dyes - of the coumarin series for synthetic fibres and plastics
BE795696A (nl) * 1972-02-28 1973-08-21 Agfa Gevaert Nv Voor warmte gevoelige materialen
US3919238A (en) 1973-06-06 1975-11-11 Morton Norwich Products Inc 9-(Substituted amino)imidazo(4,5-f) quinolines
JPS5025595A (pt) 1973-07-09 1975-03-18
SU548608A1 (ru) * 1975-07-16 1977-02-28 Московский Ордена Ленина И Ордена Трудового Красного Знамени Государственный Университет Им.М.В.Ломоносова Способ получени замещенных пиррохинолинов
JPS58170506A (ja) 1982-03-30 1983-10-07 Sumitomo Chem Co Ltd 変異原性物質の処理法
JPH0615036B2 (ja) 1984-03-27 1994-03-02 住友化学工業株式会社 フタロシアニンが結合したシリカゲルおよびそれを用いる多環系有機物質の処理法
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4777052A (en) 1987-01-06 1988-10-11 American Health Foundation Method of treating a foodstuff to inhibit the development of mutagens and related product
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
WO1989007441A1 (en) 1988-02-10 1989-08-24 The Regents Of The University Of California 6-amino-1,2-benzopyrone antitumorigenic agents and method
WO1990008529A2 (en) * 1989-01-23 1990-08-09 Lehigh University 7-alkoxycoumarins, dihydropsoralens, and benzodipyranones as photo-activated therapeutic agents and inhibitors of epidermal growth factor
DE68913306T2 (de) 1989-12-27 1994-05-26 Nestle Sa Reaktionsprodukt eines gepfropften Dextranomeres und eines Phthalocyaninfarbstoffs und dessen Verwendung.
JP3047434B2 (ja) 1990-03-27 2000-05-29 株式会社トクヤマ フォトクロミック成形体
JP3406600B2 (ja) * 1992-05-01 2003-05-12 興和株式会社 キノリン誘導体又はその塩，及びこれを含有する心疾患治療剤
JPH08512197A (ja) 1993-04-07 1996-12-24 リガンド・ファーマシューティカルズ・インコーポレーテッド 受容体アゴニストのスクリーニング方法
JP2822848B2 (ja) 1993-06-28 1998-11-11 株式会社ニコン 調光プラスチックレンズ及びその製造方法
US5677336A (en) * 1993-10-21 1997-10-14 Ligand Pharmaceuticals Incorporated Non-steroid androgen receptor antagonist compounds and methods
US6696459B1 (en) * 1994-12-22 2004-02-24 Ligand Pharmaceuticals Inc. Steroid receptor modulator compounds and methods
WO1996019458A2 (en) 1994-12-22 1996-06-27 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5696127A (en) 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
EP0933351A1 (en) 1994-12-30 1999-08-04 Ligand Pharmaceuticals Incorporated Tricyclic retinoids, methods for their production and use
MX9707594A (es) * 1995-04-04 1997-12-31 Novartis Ag Polimero de sustrato de crecimiento celular.
AU5426596A (en) 1995-05-16 1996-11-29 Salk Institute For Biological Studies, The Modulators for new members of the steroid/thyroid superfamily of receptors
WO1996041013A1 (en) 1995-06-07 1996-12-19 Ligand Pharmaceuticals Incorporated Method for screening for receptor agonists and antagonists
KR100625255B1 (ko) 1995-10-06 2008-01-30 리간드 파마슈티칼스 인코포레이티드 다이머-선택적rxr변조물질및그의사용방법
AU728178B2 (en) 1996-06-27 2001-01-04 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
CA2259031C (en) 1996-06-27 2006-10-24 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US6017924A (en) * 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
ID18046A (id) 1996-08-20 1998-02-19 Takeda Chemical Industries Ltd Senyawa siklik campuran, pembuatan dan penngunaannya.
CA2285402A1 (en) 1997-04-25 1998-11-05 Kohei Notoya Amide derivatives, their production and use
JPH1129471A (ja) * 1997-07-04 1999-02-02 Nippon Chemiphar Co Ltd クマリン誘導体を薬効成分として含有する肝疾患治療剤
US6380207B2 (en) * 1998-02-13 2002-04-30 Abbott Laboratories Glucocortiocoid-selective antiinflammatory agents
US6506766B1 (en) * 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
US6001846A (en) * 1998-02-17 1999-12-14 Ligand Pharmaceuticals Incorporated Process for the preparation of 1,2-dihydroquinolines
EP1077919A1 (en) 1998-05-11 2001-02-28 Novo Nordisk A/S New compounds, their preparation and use
US6093826A (en) * 1998-06-08 2000-07-25 Ligand Pharmaceuticals Incorporated Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines
GB9819019D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds II
US6255324B1 (en) * 1998-11-25 2001-07-03 Ned D. Heindel Amino-and mercurio-substituted 4′,5'-dihydropsoralens and therapeutical uses thereof
US6358948B1 (en) * 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
EP1212330B1 (en) 1999-08-27 2006-04-19 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
CA2378298A1 (en) * 1999-08-27 2001-03-08 Lawrence G. Hamann 8-substituted-6-trifluoromethyl-9-pyrido¬3,2-g|quinoline compounds as androgen receptor modulators
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6172241B1 (en) * 1999-10-15 2001-01-09 Ligand Pharmaceuticals Incorporated Process for the preparation of 1,2-dihydroquinolines
KR100397950B1 (ko) * 2000-01-24 2003-09-19 주식회사 겟웰바이오 데커시놀 또는 이의 유도체를 포함하는 진통제 조성물
EP1491524B1 (en) * 2000-08-24 2009-02-18 University of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7026484B2 (en) * 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
US7214690B2 (en) 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
EP1414795A4 (en) * 2001-07-31 2006-03-01 Bristol Myers Squibb Co BICYCLIC MODULATORS OF THE FUNCTION OF THE ANDROGEN RECEPTOR
DE20301728U1 (de) * 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
AR040783A1 (es) * 2002-10-11 2005-04-20 Ligand Pharm Inc 5-(1',1'-cicloaquil/alquenil) metiliden-1,2 -dihidro-5-h-cromeno [3,4- f] quiinolinas como compuestos moduladores selectivos de receptores de progesterona
CL2003001544A1 (es) * 2002-10-11 2005-01-07 Ligand Pharm Inc Compuestos derivados de 5-cicloalquenil-5h-cromeno[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, l
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
JP4709759B2 (ja) 2003-08-22 2011-06-22 リガンド・ファーマシューティカルズ・インコーポレイテッド アンドロゲン受容体モジュレーター化合物としての６−シクロアミノ−２−キノリノン誘導体
JP2007523950A (ja) * 2004-02-25 2007-08-23 リガンド・ファーマシューティカルズ・インコーポレイテッド グルココルチコイド受容体モジュレーター化合物および使用方法
WO2005090282A1 (en) 2004-03-12 2005-09-29 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
MX2007009784A (es) * 2005-06-17 2007-09-26 Ligand Pharm Inc Compuestos moduladores de receptores de androgenos y metodos.
AR057656A1 (es) * 2005-07-01 2007-12-12 Ligand Pharm Inc Compuestos moduladores de receptores de androgeno y metodods relacionados
US20090203725A1 (en) * 2005-12-21 2009-08-13 Cornelis Arjan Van Oeveren Androgen Receptor Modulator Compounds and Methods
EP2222636B1 (en) 2007-12-21 2013-04-10 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof

Also Published As

Publication number Publication date
CA2434299C (en) 2011-01-25
CN100590124C (zh) 2010-02-17
US20100210678A1 (en) 2010-08-19
US20070293528A9 (en) 2007-12-20
CN1492869A (zh) 2004-04-28
EP1363909B1 (en) 2016-10-12
EP1363909A2 (en) 2003-11-26
WO2002066475A2 (en) 2002-08-29
CA2434299A1 (en) 2002-08-29
US20020183346A1 (en) 2002-12-05
CN101215286A (zh) 2008-07-09
JP4578053B2 (ja) 2010-11-10
US7026484B2 (en) 2006-04-11
JP2009161550A (ja) 2009-07-23
WO2002066475A3 (en) 2003-01-23
US20060128740A1 (en) 2006-06-15
AU2002236114A1 (en) 2002-09-04
JP2013040197A (ja) 2013-02-28
JP2004524309A (ja) 2004-08-12
MXPA03007421A (es) 2003-12-04
US7727980B2 (en) 2010-06-01

Similar Documents

Publication Publication Date Title
BR0207549A (pt) Compostos tricìclicos moduladores de receptor de androgênio e métodos
BR0113930A (pt) Compostos heterocìclicos de ligação aos receptores de quimiocina
BR0115482A (pt) Composição de sacralose melhorada e processo para sua preparação
DE60325025D1 (de) Modulatoren des vanilloidrezeptors
BR9915515B1 (pt) composiÇço curÁvel de multicomponentes.
HN1998000175A (es) Imidazotriazininas
BR0305842A (pt) Mistura curável, e, método
DE60213276D1 (de) 1,2,4-thiadiazoliumverbindungen als melanocortinrezeptor-modulatoren
HN1998000118A (es) 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
DK1527035T3 (da) Kontinuerlig fremgangsmåde til alkyleringen af carbonhydrider
YU75601A (sh) Postupak za pripremanje modulatora nesteroidnih glukokortikoidnih receptora
BR9806852A (pt) Antagonistas receptores de vitronectina
FI20010335A0 (fi) Järjestely paperinvalmistusprosessin virtausten sekoittamiseksi
PT1189970E (pt) Aditivo carboxi-funcional para a condensacao de poliamidas
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
BR0115065A (pt) Dispositivo de radiotelefonia formatável
HRP20041224A2 (en) Cck-1 receptor modulators
BR0213481A (pt) Sondas
EA200100854A1 (ru) Кальций-литические соединения
DE60201256D1 (de) Elektrooptischer wanderwellenmodulator
DE60110517D1 (de) Lichtgesteuerter Lichtmodulator
PT941975E (pt) Cimento para injeccao contendo inibidores de corrosao
BR0307978A (pt) Composição alvejante
BR9808664A (pt) Processo para preparar eprosartan
DE50200900D1 (de) Fixiereinrichtung

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time